K
Kimberly P. Dunsmore
Researcher at Virginia Tech
Publications - 59
Citations - 2296
Kimberly P. Dunsmore is an academic researcher from Virginia Tech. The author has contributed to research in topics: Minimal residual disease & Medicine. The author has an hindex of 20, co-authored 47 publications receiving 1627 citations. Previous affiliations of Kimberly P. Dunsmore include Boston Children's Hospital & University of Virginia.
Papers
More filters
Journal ArticleDOI
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
Yu Liu,John Easton,Ying Shao,Jamie L. Maciaszek,Zhaoming Wang,Mark R. Wilkinson,Kelly McCastlain,Michael N. Edmonson,Stanley Pounds,Lei Shi,Xin Zhou,Xiaotu Ma,Edgar Sioson,Yongjin Li,Michael Rusch,Pankaj Gupta,Deqing Pei,Cheng Cheng,Malcolm A. Smith,Jaime M. Guidry Auvil,Daniela S. Gerhard,Mary V. Relling,Naomi J. Winick,Andrew J. Carroll,Nyla A. Heerema,Elizabeth A. Raetz,Meenakshi Devidas,Cheryl L. Willman,Richard C. Harvey,William L. Carroll,Kimberly P. Dunsmore,Stuart S. Winter,Brent L. Wood,Brian P. Sorrentino,James R. Downing,Mignon L. Loh,Stephen P. Hunger,Jinghui Zhang,Charles G. Mullighan +38 more
TL;DR: Using integrated genomic analysis of 264 T-ALL cases, 106 putative driver genes are identified and new mechanisms of coding and noncoding alteration are described, which suggests that different signaling pathways have distinct roles according to maturational stage.
Journal ArticleDOI
High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia
David Wu,Anna Sherwood,Jonathan R. Fromm,Stuart S. Winter,Kimberly P. Dunsmore,Mignon L. Loh,Harvey A. Greisman,Daniel E. Sabath,Brent L. Wood,Harlan Robins +9 more
TL;DR: Next-generation sequencing of lymphoid receptor gene repertoire may improve clinical diagnosis and subsequent MRD monitoring of lymphoproliferative disorders and lower the threshold of detection for MRD and affect treatment decisions.
Journal ArticleDOI
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Karen L. Bride,Tiffaney Vincent,Soo Yeon Im,Richard Aplenc,David M. Barrett,William L. Carroll,Robin Carson,Yunfeng Dai,Meenakshi Devidas,Kimberly P. Dunsmore,Tori Fuller,Tina Glisovic-Aplenc,Terzah M. Horton,Stephen P. Hunger,Mignon L. Loh,Shannon L. Maude,Elizabeth A. Raetz,Stuart S. Winter,Stephan A. Grupp,Michelle L. Hermiston,Brent L. Wood,David T. Teachey +21 more
TL;DR: It is demonstrated that blasts from patients with T-ALL have robust surface CD38 surface expression and that this expression remains stable after exposure to multiagent chemotherapy, suggesting that CD38 may be an ideal target for targeted immunotherapy.
Journal ArticleDOI
Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
Stuart S. Winter,Kimberly P. Dunsmore,Meenakshi Devidas,Brent L. Wood,Natia Esiashvili,Zhiguo Chen,Nancy Eisenberg,Nikki Briegel,Robert J. Hayashi,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Andrew J. Carroll,Nyla A. Heerema,Barbara L. Asselin,Paul S. Gaynon,Michael J. Borowitz,Mignon L. Loh,Karen R. Rabin,Elizabeth A. Raetz,Patrick A. Zweidler-McKay,Naomi J. Winick,William L. Carroll,Stephen P. Hunger +22 more
TL;DR: It is established that ABFM with C-MTX was superior to ABFM plus HDMTX for T-ALL in approximately 90% of patients who received CRT, with later timing for those receivingHDMTX.
Journal ArticleDOI
T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434
Brent L. Wood,Stuart S. Winter,Kimberly P. Dunsmore,Meenakshi Devidas,Si Chen,Barbara L. Asselin,Natia Esiashvili,Mignon L. Loh,Naomi J. Winick,William L. Carroll,Elizabeth A. Raetz,Stephen P. Hunger +11 more
TL;DR: All 3 immunophenotypic groups showed excellent 5-year EFS and OS that were not statistically different and in all 3 groups, most events occurred within 12 months from diagnosis and plateaued after 2 years, although events generally occurred earlier for ETP and Near- ETP than Not-ETP.